Evolution of cyclophotocoagulation

Ndulue, Jideofor K; Rahmatnejad, Kamran; Sanvicente, Carina; Wizov, Sheryl S.; Moster, Marlene R.

doi:10.4103/jovr.jovr_190_17

Cited by 69 publications

(43 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, laser treatments work by lowering the IOP either by increasing the aqueous drainage or by lowering the aqueous production, as in transscleral cyclophotocoagulation (TSCPC). In TSCPC, laser is transmitted via the sclera to the melanin in the pigment cell of the ciliary body epithelium 5. Two TSCPC methods exist: traditional continuous-wave (CW-TSCPC) and more recently, MicroPulse ® TSCPC (µP-TSCPC) (Iridex, Mountain View, CA, USA).…”

Section: Introductionmentioning

confidence: 99%

Outcome Of MicroPulse® Transscleral Photocoagulation In Different Types Of Glaucoma

Habash¹,

Alahmadi²

2019

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate the safety and efficacy of MicroPulse® transscleral cyclophotocoagulation (µP-TSCPC) up to 24-months follow-up using a standardized fixed protocol in patients with various types of glaucoma.MethodsProspective, nonrandomized, non-comparative interventional case series of µP-TSCPC performed by a single glaucoma surgeon at tertiary hospitals between May 2017 and May 2019.ResultsA total of 71 eyes of 68 patients (39 males, 29 females) aged 60.0 years (13–89 years) were treated with µP-TSCPC. The most common diagnosis was neovascular glaucoma. The safety index of corrected distance visual acuity (CDVA) was 1.0, i.e. there was no significant change in CDVA postoperatively compared to baseline CDVA. The median baseline IOP was 35.0 mmHg (21.0–70.0 mmHg), which was reduced to 16 mmHg (8–32 mmHg) at 12 months/last follow-up postoperatively (p<0.001, Wilcoxon signed-rank test). The median reduction in IOP was 52% (0.0–89%) at 12 months/last follow-up postoperatively compared to baseline. The median number of medications was 5 (3–5) at baseline compared to 4 (2–4) at 12 months/last follow-up postoperatively (p<0.001, Wilcoxon signed-rank test). The percent of eyes treated with systemic glaucoma medication was 62% (44) at baseline compared to 0% (0) at 12 months/last follow-up postoperatively. The postoperative surgical success of 90%, 91.4%, and 95.7% at 2 weeks, 3 months, and 6 months respectively then remains unchanged. No significant adverse events or complications were observed.ConclusionµP-TSCPC demonstrated good efficacy and safety profiles with minimal vision-threatening complications in treating a variety of glaucoma types.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcome Of MicroPulse® Transscleral Photocoagulation In Different Types Of Glaucoma

Habash¹,

Alahmadi²

2019

OPTH

View full text Add to dashboard Cite

show abstract

“… 78 – 80 Laser treatment could be used in two ways: it can increase the aqueous outflow through procedures such as laser trabeculoplasty, 81 , 82 or it can decrease aqueous production by laser cyclophotocoagulation through transscleral or endoscopic approaches. 83 , 84 In this SIG, Dr Johnstone presented a novel pressure-lowering mechanism using transscleral micropulse laser, which we focus on in this review.…”

Section: New Treatment Targeting the Aqueous Outflow Pathwaymentioning

confidence: 99%

Minimally Invasive Glaucoma Surgery: What Do We Know? Where Should We Go?

Chen

Wang

2020

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

With the arrival of a plethora of new and revolving minimally invasive glaucoma surgery techniques, glaucoma specialists currently are fortunate to have various surgical options that aim to recovery of the function of the aqueous outflow system in different ways. Meanwhile, the aqueous outflow system has become the hot point of researching. In ARVO 2019, a special interest group session was held on new perspectives on minimally invasive glaucoma surgery. Ten surgeons, clinical professors, and experimental scientists were invited to report their latest studies and discussed on five hot topics in this special interest group. This review summarizes the special interest group session and posts the issues of greatest concern, providing insight to the aqueous outflow system and areas that require further study.

show abstract

“…[4][5][6] Hence, cyclodestructive procedures are usually reserved for refractory glaucoma in eyes with little or no visual potential. [7][8][9] High-intensity focused ultrasound (HIFU) was first proposed as an alternative for lowering IOP in the 1980s. [6,[10][11][12] Following recent breakthroughs in HIFU technology, a new cyclocoagulation device, the EyeOP1 (EyeTechCare, Rillieux-la-Pape, France), was developed for selective thermal coagulation of the ciliary body, sparing the adjacent ocular structures.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of ultrasonic circular cyclocoagulation with second-generation probe in glaucoma: A retrospective study

et al. 2020

View full text Add to dashboard Cite

BackgroundTo assess the efficacy and safety of the second-generation probe of ultrasonic circular cyclocoagulation (UC3) in naive or refractory glaucoma, with a 6-month follow-up. MethodsA retrospective consecutive case-series study included patients having a UC3 procedure with the second-generation probe of the EyeOP1 device, intraocular pressure (IOP) � 21 mmHg and under maximum tolerated medical treatment, with or without previous glaucoma surgery. Surgical success was defined at the 6-month post-operative visit as IOP > 5 and � 21 mmHg with IOP reduction � 20% from baseline, without any reoperation, and visual acuity better than negative light perception. Results100 patients were included and 97 (97.0%; 97 eyes) attended the 6-month follow-up. At 6 months, surgical success was obtained in 48 eyes (49.5%). Intraocular pressure was reduced from a mean ± SD preoperative value of 28.0 ± 5.6 mmHg to 19.3 ± 7.1 mmHg at 6 months (p<0.0001). The proportion of eyes requiring oral acetazolamide decreased from 57.0% to 30.0% between baseline and 6 months after surgery (p = 0.0007). We observed 15 (15.0%) cases of postsurgical macular edema, 8 (8.0%) of hypotony, and 20 (20.0%) of visual acuity loss > 2 Snellen lines. Postsurgical macular edema was associated with a history of epiretinal membranes, uveitis or retinal detachment. Risk factors for hypotony were a history of diabetes or trabeculectomy. ConclusionsThe second-generation UC3 probe significantly reduced IOP in eyes with naive and refractory glaucoma but severe post-operative complications were often observed. Further Citation: Chamard C, Daien V, Han H, Greenfield DS, Villain M (2020) Efficacy and safety of ultrasonic circular cyclocoagulation with secondgeneration probe in glaucoma: A retrospective study. PLoS ONE 15(1): e0227389. https://doi.org/ 10.studies are needed to better identify responders and decrease the high risk for complications associated with the procedure. MethodsThis study followed the STROBE checklist for reporting observational study findings. [22] Design Retrospective consecutive case-series study with 6-month follow-up. Examinations were performed before the procedure and 1 week, 1, 3, and 6 months afterwards. Preoperative hypotensive medications remained unchanged during the first month except for cases of hypotony, then adjusted if necesary during follow-up. Re-treatment was proposed after a minimum of 3 months if surgical success was not achieved. Patients were retreated with a second UC3 procedure, DL-CPC (diode laser cyclophotocoagulation) or trabeculectomy when IOP target was not reached, according to glaucoma stage, prior treatments and visual potential.

show abstract

Evolution of cyclophotocoagulation

Cited by 69 publications

References 71 publications

<p>Outcome Of MicroPulse<sup>®</sup> Transscleral Photocoagulation In Different Types Of Glaucoma</p>

<p>Outcome Of MicroPulse<sup>®</sup> Transscleral Photocoagulation In Different Types Of Glaucoma</p>

Minimally Invasive Glaucoma Surgery: What Do We Know? Where Should We Go?

Efficacy and safety of ultrasonic circular cyclocoagulation with second-generation probe in glaucoma: A retrospective study

Contact Info

Product

Resources

About